Cargando…

Can Zoledronic Acid be Beneficial for Promoting Tumor Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy?

The antitumor effect of bisphosphonates (BPs) is under increasing scrutiny. Preclinical and clinical evidence has shown that BPs might sensitize breast tumors to chemotherapy. Here, we present a review of current preclinical and clinical evidence for antitumor effects of BPs, and evaluate how BPs mi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Charehbili, Ayoub, Fontein, Duveken B. Y., Kroep, Judith R., Liefers, Gerrit-Jan, Nortier, Johannes W. R., van de Velde, Cornelis J. H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2013
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470143/ https://www.ncbi.nlm.nih.gov/pubmed/26237143 http://dx.doi.org/10.3390/jcm2040188

Ejemplares similares

Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials
por: Kroep, J.R., et al.
Publicado: (2015)

Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01)
por: de Groot, Stefanie, et al.
Publicado: (2019)

Axillary staging in breast cancer patients treated with neoadjuvant chemotherapy in two Dutch phase III studies
por: Vriens, Birgit E.P., et al.
Publicado: (2017)

Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy
por: de Groot, A. F., et al.
Publicado: (2019)

Tumor‐stroma ratio is associated with Miller‐Payne score and pathological response to neoadjuvant chemotherapy in HER2‐negative early breast cancer
por: Hagenaars, Sophie C., et al.
Publicado: (2021)

Thyroid function alters during neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01)
por: de Groot, S., et al.
Publicado: (2015)

Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer
por: Blok, Erik J., et al.
Publicado: (2017)

The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer
por: Coleman, R E, et al.
Publicado: (2010)

Beneficial Effects of Zoledronic Acid on Tendons of the Osteogenesis Imperfecta Mouse (Oim)
por: Chretien, Antoine, et al.
Publicado: (2023)

Can breast MRI help in the management of women with breast cancer treated by neoadjuvant chemotherapy?
por: Warren, R M L, et al.
Publicado: (2004)

Immunological subtypes in breast cancer are prognostic for invasive ductal but not for invasive lobular breast carcinoma
por: Engels, C C, et al.
Publicado: (2014)

Adjuvant Zoledronic Acid in High‐Risk Giant Cell Tumor of Bone: A Multicenter Randomized Phase II Trial
por: Lipplaa, Astrid, et al.
Publicado: (2019)

Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01)
por: de Groot, Stefanie, et al.
Publicado: (2016)

Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study)
por: Hasegawa, Yoshie, et al.
Publicado: (2015)

Is neoadjuvant androgen deprivation therapy beneficial in prostate cancer treated with definitive radiotherapy?
por: Eom, Keun-Yong, et al.
Publicado: (2014)

Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial
por: de Groot, Stefanie, et al.
Publicado: (2020)

The clinical value of HER-2 overexpression and PIK3CA mutations in the older breast cancer population: a FOCUS study analysis
por: Engels, Charla C., et al.
Publicado: (2016)

Addition of Zoledronate to Chemotherapy in Patients with Osteosarcoma Treated with Limb-Sparing Surgery: A Phase III Clinical Trial
por: Li, Shenglong, et al.
Publicado: (2019)

Neoadjuvant zoledronic acid for HER2-positive breast cancer: the Zo-NAnTax trial
por: Crocamo, Susanne, et al.
Publicado: (2019)

Enhanced Osteogenic Differentiation in Zoledronate-Treated Osteoporotic Patients
por: Dalle Carbonare, Luca, et al.
Publicado: (2017)

Serum levels of IGF-1 and IGF-BP3 are associated with event-free survival in adult Ewing sarcoma patients treated with chemotherapy
por: de Groot, Stefanie, et al.
Publicado: (2017)

P-glycoprotein expression in locally advanced breast cancer treated by neoadjuvant chemotherapy.
por: Dixon, A. R., et al.
Publicado: (1992)

Two decades of percutaneous transjejunal biliary intervention for benign biliary disease: a review of the intervention nature and complications
por: Fontein, Duveken B. Y., et al.
Publicado: (2011)

Intralesional zoledronate: A novel therapy to treat fibrous dysplasia
por: Gopinathan, Nirmal Raj, et al.
Publicado: (2020)

Lymphovascular invasion can be better than pathologic complete response to predict prognosis in breast cancer treated with neoadjuvant chemotherapy
por: Ryu, Young Jae, et al.
Publicado: (2018)

Can ageing be beneficial?
por: Frenk, Stephen, et al.
Publicado: (2017)

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
por: Miller, P. D., et al.
Publicado: (2016)

The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study
por: de Groot, Stefanie, et al.
Publicado: (2015)

DCE-MRI radiomics nomogram can predict response to neoadjuvant chemotherapy in esophageal cancer
por: Qu, Jinrong, et al.
Publicado: (2022)

The applicability of Magseed® for targeted axillary dissection in breast cancer patients treated with neoadjuvant chemotherapy
por: Reitsamer, R., et al.
Publicado: (2021)

The impact of the perception of treatment choice on satisfaction with treatment, experienced chemotherapy burden and current quality of life
por: Jansen, S J T, et al.
Publicado: (2004)

Neoadjuvant Chemotherapy in Invasive Bladder Cancer
por: Oliver, R.T.D.
Publicado: (1991)

The role of IRAK1 in breast cancer patients treated with neoadjuvant chemotherapy
por: Yang, Muwen, et al.
Publicado: (2019)

Biomarkers in precision therapy in colorectal cancer
por: Reimers, Marlies S., et al.
Publicado: (2013)

On-treatment biomarkers can improve prediction of response to neoadjuvant chemotherapy in breast cancer
por: Bownes, Richard J., et al.
Publicado: (2019)

Gorham–Stout disease of the proximal fibula treated with radiotherapy and zoledronic acid
por: Yerganyan, V.V., et al.
Publicado: (2015)

Dietary nitrate improves jaw bone remodelling in zoledronate‐treated mice
por: Pan, Wen, et al.
Publicado: (2023)

The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis
por: Engels, C. C., et al.
Publicado: (2015)

Prognostic value of HLA class I, HLA-E, HLA-G and Tregs in rectal cancer: a retrospective cohort study
por: Reimers, Marlies S, et al.
Publicado: (2014)

Ignorance can be evolutionarily beneficial
por: Field, Jared M., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7eqb576gl28on0r1rfr7p47vus